These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Relevance of posttransplant HLA-II antibodies production on long-term survival of renal allograft].
    Author: Liu ZH, Shen B, Tan JM, Ding YD.
    Journal: Zhonghua Yi Xue Za Zhi; 2007 Jul 24; 87(28):1978-80. PubMed ID: 17923038.
    Abstract:
    OBJECTIVE: To evaluate the clinic relevance of anti-HLA-II antibodies on allograft long-term survival. METHODS: Perioperative sera of 118 cadaveric kidney recipients were tested by ELISA for anti-HLA-II antibodies in our prospective cohort study. All recipients who divided into different groups according to HLA antibody production were followed-up. RESULTS: (1) Anti-HLA-II antibody-positive recipients were associated with significantly lower graft survival (78.6% vs 84.4%; 71.4% vs 80.0%; P = 0.002) and death-censored graft survival (85.7% vs 92.2%; 82.1% vs 90.0%; P = 0.003) at 3 and 4 years compared to antibody-negative recipients. (2) Anti-HLA-II antibody-positive recipients were associated with a significantly increased risk for decline in renal function at 3 and 4 years (39.3% vs 33.3%; 46.4% vs 38.9%, P = 0.001). (3) There was statistically non-significance difference in late-acute rejection rate between two groups (10.7% vs 13.3%, P > 0.05). CONCLUSION: Posttransplant HLA-II antibodies perhaps are one of the most important influential facts on allograft long-term survival and could be used to predict the prognosis of allograft.
    [Abstract] [Full Text] [Related] [New Search]